Synergistic Effects of Cabozantinib and EGFR-Specific CAR-NK-92 Cells in Renal Cell Carcinoma
The chimeric antigen receptor-modified immune effector cell (CAR-T and CAR-NK) therapies are newly developed adoptive treatments of cancers. However, their therapeutic efficacy against solid tumors is limited. Combining CAR-T or CAR-NK cells with chemotherapeutic drugs to treat solid tumor may be a...
Saved in:
Main Authors: | Qing Zhang, Kang Tian, Jinjing Xu, Haixu Zhang, Liantao Li, Qiang Fu, Dafei Chai, Huizhong Li, Junnian Zheng |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2017-01-01
|
Series: | Journal of Immunology Research |
Online Access: | http://dx.doi.org/10.1155/2017/6915912 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
NK-92 cells activated by IL-2 inhibit the progression of endometriosis in vitro
by: Jun Yao, et al.
Published: (2024-12-01) -
Brain Complete Response to Cabozantinib prior to Radiation Therapy in Metastatic Renal Cell Carcinoma
by: An Uche, et al.
Published: (2019-01-01) -
Off-the-shelf CAR-NK cells targeting immunogenic cell death marker ERp57 execute robust antitumor activity and have a synergistic effect with ICD inducer oxaliplatin
by: Jichao Sun, et al.
Published: (2024-07-01) -
Cabozantinib Cutaneous Toxicity—Comprehensive Review
by: Cristina Violeta Tutunaru, et al.
Published: (2025-01-01) -
Novel gene manipulation approaches to unlock the existing bottlenecks of CAR-NK cell therapy
by: Fatemeh Dehghan, et al.
Published: (2025-02-01)